Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eloiza Helena Tajara is active.

Publication


Featured researches published by Eloiza Helena Tajara.


Proceedings of the National Academy of Sciences of the United States of America | 2001

The contribution of 700,000 ORF sequence tags to the definition of the human transcriptome

Anamaria A. Camargo; Helena P.B. Samaia; Emmanuel Dias-Neto; Daniel F. Simão; Italo A. Migotto; Marcelo R. S. Briones; Fernando Ferreira Costa; Maria Aparecida Nagai; Sergio Verjovski-Almeida; Marco A. Zago; Luís Eduardo Coelho Andrade; Helaine Carrer; Enilza M. Espreafico; Angelita Habr-Gama; Daniel Giannella-Neto; Gustavo H. Goldman; Arthur Gruber; Christine Hackel; Edna T. Kimura; Rui M. B. Maciel; Suely Kazue Nagahashi Marie; Elizabeth A. L. Martins; Marina P. Nobrega; Maria Luisa Paçó-Larson; Maria Inês de Moura Campos Pardini; Gonçalo Amarante Guimarães Pereira; João Bosco Pesquero; Vanderlei Rodrigues; Silvia Regina Rogatto; Ismael D.C.G. Silva

Open reading frame expressed sequences tags (ORESTES) differ from conventional ESTs by providing sequence data from the central protein coding portion of transcripts. We generated a total of 696,745 ORESTES sequences from 24 human tissues and used a subset of the data that correspond to a set of 15,095 full-length mRNAs as a means of assessing the efficiency of the strategy and its potential contribution to the definition of the human transcriptome. We estimate that ORESTES sampled over 80% of all highly and moderately expressed, and between 40% and 50% of rarely expressed, human genes. In our most thoroughly sequenced tissue, the breast, the 130,000 ORESTES generated are derived from transcripts from an estimated 70% of all genes expressed in that tissue, with an equally efficient representation of both highly and poorly expressed genes. In this respect, we find that the capacity of the ORESTES strategy both for gene discovery and shotgun transcript sequence generation significantly exceeds that of conventional ESTs. The distribution of ORESTES is such that many human transcripts are now represented by a scaffold of partial sequences distributed along the length of each gene product. The experimental joining of the scaffold components, by reverse transcription–PCR, represents a direct route to transcript finishing that may represent a useful alternative to full-length cDNA cloning.


Proceedings of the National Academy of Sciences of the United States of America | 2003

The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags

Helena Brentani; Otavia L. Caballero; Anamaria A. Camargo; Aline M. da Silva; Wilson A. Silva; Emmanuel Dias Neto; Marco Grivet; Arthur Gruber; Pedro Edson Moreira Guimarães; Winston Hide; Christian Iseli; C. Victor Jongeneel; Janet Kelso; Maria Aparecida Nagai; Elida B. Ojopi; Elisson Osório; Eduardo M. Reis; Gregory J. Riggins; Andrew J.G. Simpson; Sandro J. de Souza; Brian J. Stevenson; Robert L. Strausberg; Eloiza Helena Tajara; Sergio Verjovski-Almeida

Whereas genome sequencing defines the genetic potential of an organism, transcript sequencing defines the utilization of this potential and links the genome with most areas of biology. To exploit the information within the human genome in the fight against cancer, we have deposited some two million expressed sequence tags (ESTs) from human tumors and their corresponding normal tissues in the public databases. The data currently define ≈23,500 genes, of which only ≈1,250 are still represented only by ESTs. Examination of the EST coverage of known cancer-related (CR) genes reveals that <1% do not have corresponding ESTs, indicating that the representation of genes associated with commonly studied tumors is high. The careful recording of the origin of all ESTs we have produced has enabled detailed definition of where the genes they represent are expressed in the human body. More than 100,000 ESTs are available for seven tissues, indicating a surprising variability of gene usage that has led to the discovery of a significant number of genes with restricted expression, and that may thus be therapeutically useful. The ESTs also reveal novel nonsynonymous germline variants (although the one-pass nature of the data necessitates careful validation) and many alternatively spliced transcripts. Although widely exploited by the scientific community, vindicating our totally open source policy, the EST data generated still provide extensive information that remains to be systematically explored, and that may further facilitate progress toward both the understanding and treatment of human cancers.


International Journal of Cancer | 2007

Annexin 1: differential expression in tumor and mast cells in human larynx cancer

Rosana Silistino-Souza; Flavia Cristina Rodrigues-Lisoni; Patrícia Maluf Cury; José Victor Maniglia; Luis Sérgio Raposo; Eloiza Helena Tajara; Helen Christian; Sonia Maria Oliani

Annexin 1 protein (ANXA1) expression was evaluated in tumor and mast cells in human larynx cancer and control epithelium. The effect of the exogenous ANXA1 (peptide Ac 2‐26) was also examined during the cellular growth of the Hep‐2 human larynx epidermoid carcinoma cell line. This peptide inhibited the proliferation of the Hep‐2 cells within 144 hr. In surgical tissue specimens from 20 patients with larynx cancer, ultrastructural immunocytochemistry analysis showed in vivo down‐regulation of ANXA1 expression in the tumor and increased in mast cells and Hep‐2 cells treated with peptide Ac2‐26. Combined in vivo and in vitro analysis demonstrated that ANXA1 plays a regulatory role in laryngeal cancer cell growth. We believe that a better understanding of the regulatory mechanisms of ANXA1 in tumor and mast cells may lead to future biological targets for the therapeutic intervention of human larynx cancer.


Cancer Genetics and Cytogenetics | 1988

New common fragile sites

Frederick Hecht; Eloiza Helena Tajara; David Lockwood; Avery A. Sandberg; Barbara K. Hecht

We report the finding of a large number of new common fragile sites. Thirty-one (56%) of 55 common fragile sites found in a sample of human lymphocytes were ones not described at the Eighth International Workshop on Human Gene Mapping (HGM 8). The sample consisted of 3023 lymphocytes from nine unrelated individuals with a history of genitourinary malignancy. The lymphocytes were challenged in culture with aphidicolin (Apc), fluorodeoxyuridine (FUdR), 5-azacytidine (Aza), and bromodeoxyuridine (BrdU). Thirteen of the new common fragile sites were induced by Apc and FUdR, nine by Aza, five by BrdU, and four by combined means. The sites induced by Apc and FUdR were cross-induced by BrdU. The fragile sites induced by a diminished concentration of Aza were largely located in heterochromatic regions and were cross-induced by BrdU and FUdR. Exposure to BrdU for 24 hours, a technique hitherto restricted to rare fragile sites, induced several common fragile sites. Control lymphocytes had far fewer gaps and breaks, but these were clustered predominantly at high-expression fragile sites. Because more than half of the common fragile sites in this study were new, it is clear that much remains to be learned. Because the classes of fragile sites reveal cross-induction, we propose that fragile sites share structures in DNA.


BMC Research Notes | 2008

Global gene expression profiling of oral cavity cancers suggests molecular heterogeneity within anatomic subsites

Patricia Severino; Adriana M Alvares; Pedro Michaluart; Oswaldo Keith Okamoto; Fabio Daumas Nunes; Carlos Alberto Moreira-Filho; Eloiza Helena Tajara

BackgroundOral squamous cell carcinoma (OSCC) is a frequent neoplasm, which is usually aggressive and has unpredictable biological behavior and unfavorable prognosis. The comprehension of the molecular basis of this variability should lead to the development of targeted therapies as well as to improvements in specificity and sensitivity of diagnosis.ResultsSamples of primary OSCCs and their corresponding surgical margins were obtained from male patients during surgery and their gene expression profiles were screened using whole-genome microarray technology. Hierarchical clustering and Principal Components Analysis were used for data visualization and One-way Analysis of Variance was used to identify differentially expressed genes. Samples clustered mostly according to disease subsite, suggesting molecular heterogeneity within tumor stages. In order to corroborate our results, two publicly available datasets of microarray experiments were assessed. We found significant molecular differences between OSCC anatomic subsites concerning groups of genes presently or potentially important for drug development, including mRNA processing, cytoskeleton organization and biogenesis, metabolic process, cell cycle and apoptosis.ConclusionOur results corroborate literature data on molecular heterogeneity of OSCCs. Differences between disease subsites and among samples belonging to the same TNM class highlight the importance of gene expression-based classification and challenge the development of targeted therapies.


Revista De Saude Publica | 1998

Efeitos tardios dos praguicidas organoclorados no homem

Mônica Vannucci Nunes; Eloiza Helena Tajara

Procurou-se relacionar as informacoes disponiveis sobre os organoclorados e os efeitos cronicos provocados pela exposicao. Os compostos organoclorados sao os praguicidas mais persistentes ja fabricados. Embora sejam geralmente eficientes no controle das pragas, sao importantes poluentes ambientais e potenciais causas de problemas de saude para o homem, tendo sido proibidos ou controlados na maioria dos paises. Com poucas excecoes, os efeitos tardios desses compostos sobre a saude humana sao dificeis de detectar, em funcao de dificuldades metodologicas e da extrapolacao dos resultados. A genotoxicidade esta entre os mais serios dos possiveis danos causados por esses compostos e merece atencao especial, devido a natureza irreversivel do processo. Outro ponto a ser considerado e o aumento na incidencia de alteracoes no desenvolvimento do trato reprodutivo e na fertilidade masculina observada nas ultimas decadas provavelmente decorrente do aumento da exposicao intra-uterina a compostos estrogenicos e anti-androgenicos, como os organoclorados.


BMC Medical Genomics | 2010

Genomics and proteomics approaches to the study of cancer-stroma interactions

Flávia Cristina Rodrigues-Lisoni; Paulo Peitl; Alessandra Vidotto; Giovana Mussi Polachini; José Victor Maniglia; Juliana Carmona-Raphe; Bianca Rodrigues da Cunha; Tiago Henrique; Caique F. Souza; Rodrigo A. P. Teixeira; Erica Erina Fukuyama; Pedro Michaluart; Marcos Brasilino de Carvalho; Sonia Maria Oliani; Eloiza Helena Tajara

BackgroundThe development and progression of cancer depend on its genetic characteristics as well as on the interactions with its microenvironment. Understanding these interactions may contribute to diagnostic and prognostic evaluations and to the development of new cancer therapies. Aiming to investigate potential mechanisms by which the tumor microenvironment might contribute to a cancer phenotype, we evaluated soluble paracrine factors produced by stromal and neoplastic cells which may influence proliferation and gene and protein expression.MethodsThe study was carried out on the epithelial cancer cell line (Hep-2) and fibroblasts isolated from a primary oral cancer. We combined a conditioned-medium technique with subtraction hybridization approach, quantitative PCR and proteomics, in order to evaluate gene and protein expression influenced by soluble paracrine factors produced by stromal and neoplastic cells.ResultsWe observed that conditioned medium from fibroblast cultures (FCM) inhibited proliferation and induced apoptosis in Hep-2 cells. In neoplastic cells, 41 genes and 5 proteins exhibited changes in expression levels in response to FCM and, in fibroblasts, 17 genes and 2 proteins showed down-regulation in response to conditioned medium from Hep-2 cells (HCM). Nine genes were selected and the expression results of 6 down-regulated genes (ARID4A, CALR, GNB2L1, RNF10, SQSTM1, USP9X) were validated by real time PCR.ConclusionsA significant and common denominator in the results was the potential induction of signaling changes associated with immune or inflammatory response in the absence of a specific protein.


BMC Medical Genomics | 2008

Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries

Nelson J. F. Silveira; Leonardo Varuzza; Ariane Machado-Lima; Marcelo de Souza Lauretto; Daniel G. Pinheiro; Rodrigo V. Rodrigues; Patricia Severino; Francisco G. Nobrega; Wilson A. Silva; Carlos Alberto Pereira; Eloiza Helena Tajara

BackgroundHead and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies in humans. The average 5-year survival rate is one of the lowest among aggressive cancers, showing no significant improvement in recent years. When detected early, HNSCC has a good prognosis, but most patients present metastatic disease at the time of diagnosis, which significantly reduces survival rate. Despite extensive research, no molecular markers are currently available for diagnostic or prognostic purposes.MethodsAiming to identify differentially-expressed genes involved in laryngeal squamous cell carcinoma (LSCC) development and progression, we generated individual Serial Analysis of Gene Expression (SAGE) libraries from a metastatic and non-metastatic larynx carcinoma, as well as from a normal larynx mucosa sample. Approximately 54,000 unique tags were sequenced in three libraries.ResultsStatistical data analysis identified a subset of 1,216 differentially expressed tags between tumor and normal libraries, and 894 differentially expressed tags between metastatic and non-metastatic carcinomas. Three genes displaying differential regulation, one down-regulated (KRT31) and two up-regulated (BST2, MFAP2), as well as one with a non-significant differential expression pattern (GNA15) in our SAGE data were selected for real-time polymerase chain reaction (PCR) in a set of HNSCC samples. Consistent with our statistical analysis, quantitative PCR confirmed the upregulation of BST2 and MFAP2 and the downregulation of KRT31 when samples of HNSCC were compared to tumor-free surgical margins. As expected, GNA15 presented a non-significant differential expression pattern when tumor samples were compared to normal tissues.ConclusionTo the best of our knowledge, this is the first study reporting SAGE data in head and neck squamous cell tumors. Statistical analysis was effective in identifying differentially expressed genes reportedly involved in cancer development. The differential expression of a subset of genes was confirmed in additional larynx carcinoma samples and in carcinomas from a distinct head and neck subsite. This result suggests the existence of potential common biomarkers for prognosis and targeted-therapy development in this heterogeneous type of tumor.


PLOS ONE | 2014

Inflammation and cancer: role of annexin A1 and FPR2/ALX in proliferation and metastasis in human laryngeal squamous cell carcinoma.

Thaís Santana Gastardelo; Bianca Rodrigues da Cunha; Luís Raposo; José Victor Maniglia; Patrícia Maluf Cury; Flávia Cristina Rodrigues Lisoni; Eloiza Helena Tajara; Sonia Maria Oliani

The anti-inflammatory protein annexin A1 (ANXA1) has been associated with cancer progression and metastasis, suggesting its role in regulating tumor cell proliferation. We investigated the mechanism of ANXA1 interaction with formylated peptide receptor 2 (FPR2/ALX) in control, peritumoral and tumor larynx tissue samples from 20 patients, to quantitate the neutrophils and mast cells, and to evaluate the protein expression and co-localization of ANXA1/FPR2 in these inflammatory cells and laryngeal squamous cells by immunocytochemistry. In addition, we performed in vitro experiments to further investigate the functional role of ANXA1/FPR2 in the proliferation and metastasis of Hep-2 cells, a cell line from larynx epidermoid carcinoma, after treatment with ANXA12–26 (annexin A1 N-terminal-derived peptide), Boc2 (antagonist of FPR) and/or dexamethasone. Under these treatments, the level of Hep-2 cell proliferation, pro-inflammatory cytokines, ANXA1/FPR2 co-localization, and the prostaglandin signalling were analyzed using ELISA, immunocytochemistry and real-time PCR. An influx of neutrophils and degranulated mast cells was detected in tumor samples. In these inflammatory cells of peritumoral and tumor samples, ANXA1/FPR2 expression was markedly exacerbated, however, in laryngeal carcinoma cells, this expression was down-regulated. ANXA12–26 treatment reduced the proliferation of the Hep-2 cells, an effect that was blocked by Boc2, and up-regulated ANXA1/FPR2 expression. ANXA12–26 treatment also reduced the levels of pro-inflammatory cytokines and affected the expression of metalloproteinases and EP receptors, which are involved in the prostaglandin signalling. Overall, this study identified potential roles for the molecular mechanism of the ANXA1/FPR2 interaction in laryngeal cancer, including its relationship with the prostaglandin pathway, providing promising starting points for future research. ANXA1 may contribute to the regulation of tumor growth and metastasis through paracrine mechanisms that are mediated by FPR2/ALX. These data may lead to new biological targets for therapeutic intervention in human laryngeal cancer.


Molecular Cancer | 2014

Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models

Lays Martin Sobral; Lucas Oliveira Sousa; Ricardo D. Coletta; Hamilton Cabral; Lewis J. Greene; Eloiza Helena Tajara; J. Silvio Gutkind; Carlos Curti; Andréia Machado Leopoldino

BackgroundSET/I2PP2A is a multifunctional protein that is up-regulated in head and neck squamous cell carcinoma (HNSCC). The action of SET in HNSCC tumorigenicity is unknown.MethodsStable SET knockdown by shRNA (shSET) was established in three HNSCC cell lines: HN12, HN13, and Cal27. Protein expression and phosphorylated protein levels were determined by Western blotting and immunofluorescence, cell migration and invasion were measured by functional analysis, and PP2A activity was determined using a serine/threonine phosphatase assay. A real-time PCR array was used to quantify 84 genes associated with cell motility. Metalloproteinase (MMP) activity was assessed by zymographic and fluorometric assays. HN12shSET xenograft tumors (flank and tongue models) were established in Balb/c nude mice; the xenograft characteristics and cisplatin sensitivity were demonstrated by macroscopic, immunohistochemical, and histological analyses, as well as lymph node metastasis by histology.ResultsThe HN12shSET cells displayed reduced ERK1/2 and p53 phosphorylation compared with control. ShSET reduced HN12 cell proliferation and increased the sub-G1 population of HN12 and Cal27 cells. Increased PP2A activity was also associated with shSET. The PCR array indicated up-regulation of three mRNAs in HN12 cells: vimentin, matrix metalloproteinase-9 (MMP9) and non-muscle myosin heavy chain IIB. Reduced E-cadherin and pan-cytokeratin, as well as increased vimentin, were also demonstrated as the result of SET knockdown. These changes were accompanied by an increase in MMP-9 and MMP-2 activities, migration and invasion. The HN12shSET subcutaneous xenograft tumors presented a poorly differentiated phenotype, reduced cell proliferation, and cisplatin sensitivity. An orthotopic xenograft tumor model using the HN12shSET cells displayed increased metastatic potential.ConclusionsSET accumulation has important actions in HNSCC. As an oncogene, SET promotes cell proliferation, survival, and resistance to cell death by cisplatin in vivo. As a metastasis suppressor, SET regulates invasion, the epithelial mesenchymal transition, and metastasis.

Collaboration


Dive into the Eloiza Helena Tajara's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anamaria A. Camargo

Ludwig Institute for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Andréia Machado Leopoldino

Faculdade de Medicina de São José do Rio Preto

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Arthur Gruber

University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Eny Maria Goloni-Bertollo

Faculdade de Medicina de São José do Rio Preto

View shared research outputs
Researchain Logo
Decentralizing Knowledge